NONPROFIT ORGANIZATION


VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 C.F.R. 1.9(e) AND 1.27(d)) - NONPROFIT ORGANIZATION

I house declare that I am an official empower	ared to act on behalf of the nonprofit organization identified below:
NAME OF ORGANIZATION:	Repents of the University of Minnesota
ADDRESS OF ORGANIZATION:	Morrill Hall, 100 Church Street S.E.
	Minneapolis, MN 55455
TYPE OF ORGANIZATION:	
a) (x) UNIVERSITY OR OTHER	r institution of Higher Education
b)() TAX BXEMPT UNDER IN	TERNAL REVENUE SERVICE CODE (26 U.S.C. 501(a) AND 501(c)(3)) OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED
STATES OF AMERIC	CA - (NAME OF STATE)
D () bushing a start man	(CITATION OF STATUTE
() () WOULD QUALIFY AS TA	X EXEMPT UNDER INTERNAL REVINUE SERVICE CODE (26 U.S.C. I) OF LOCATED IN THE UNITED STATES OF AMERICA
•) () WOULD QUALIFY AS NO	DIPROFIT SCIENTIFIE OR ROUGATIONAL LINDER STATINH OF
STATE OF THE UNIT OF AMERICA	TED STATES OF AMERICA IF LOCATED IN THE UNITED STATES
OF AMERICA	(NAME OF STATE) (CITATION OF STATUTE)
I hereby declare that the nonneafit accoming to	
for number of naving reduced fees under Se	on identified above qualifies as a nonprofit organization as defined in 13 C.F.R. 1.9(e) ction 41(a) and (b) of Title 35, United States Code, in regard to the invention, entitled
METHODS TO TREAT UNDESIRABLE IN	MENERESPONSES by inventor Bianca M. Conti-Fine described in application serial
no. 08/991.143 filed December 16, 1997.	awarde 1025 CANDES by inventor biblish M. Conti-Fine described in application serial
I hereby declare that rights under contract or lab ve identified invention.	aw have been conveyed to and remain with the nonprofit organization with regard to the
in the rights held by the nonprofit organization	are not exclusive, each individual, concern or organization having rights to the
invention is used below and no rights to the	invention are held by any person, other than the inventor, who could not qualify as an
1 O(d) or a second to remain the under 37 C.F.K. 1.9(c) of	er by any concern which would not qualify as a small business concern under 37 C.F.R.
1.2(a) of a numbroth organization busine sieber	F.R. 1.9(a). *NOTE: Separate verified statements are required from each named
bersell' actions of or family following that is	to the invention averring to their status as small entities. (37 C.F.R. 1.27)
NAME	
ADDRESS	
a) () INDIVIDUAL b) () SMALL BUSINE	ss concern c) (Inonpropit Organization
	o) (Mana worth and Manifold
I acknowledge the duty to file, in this applicati	on or patent, notification of any change in status resulting in loss of entitlement to small
entity status prior to paying, or at the time of p	aying, the carliest of the issue fee or any maintenance fee due after the date on which
status as a small entity is no longer appropriate	o. (37 C.F.R. 1.28(b))
-	•
I hereby declare that all statements made herei	n of my own knowledge are true and that all statements made on information and belief
are believed to be true; and further that these st	tatements were made with the knowledge that willful false statements and the like so
made are punishable by fine or imprisonment,	or both under Section 1001 of Title 18 of the United States Code, and that such willful
false statements may jeopardize the validity of	the application, any patent issuing thereof, or any patent to which this verified
statement is directed.	•
NAME James A. Severson,	Ph.D.
NAME Dalles A. Seversoll,	
TITLE Director, Health To	echnologies
ADDRESS 1100 Washington Ave	eppe South, Ste. 201; Minneapolis MN 55415-1226
SIGNATURE James /-	DATE May 15, 1998

Professional Association

JUL 1 3 1598 GROUP 1890





United States Patent Application

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that

I verily believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled: <u>METHODS TO TREAT UNDESIRABLE IMMUNE RESPONSES</u>.

The specification of which was filed on <u>December 16, 1997</u> as application serial no. <u>08/991,143</u>.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56 (see page 3 attached hereto).

I hereby claim foreign priority benefits under Title 35, United States Code, §119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on the basis of which priority is claimed:

No such applications have been filed.

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

No such applications have been filed.

I hereby claim the benefit under Title 35, United States Code, § 120/365 of any United States and PCT international application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

No such applications have been filed.


I hereby appoint the following attorney(s) and/or patent agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith:


Anglin, J. Michael Bianchi, Timothy E. Billion, Richard E. Brennan, Thomas F. Brooks, Edward J., III Clark, Barbara J. Drake, Eduardo E. Dryja, Michael A. Embretson, Janet E.	Reg. No. 24,916 Reg. No. 39,610 Reg. No. 32,836 Reg. No. 35,075 Reg. No. 40,925 Reg. No. 38,107 Reg. No. 40,594 Reg. No. 39,662 Reg. No. 39,665	Fogg, David N. Forrest, Bradley A. Harris, Robert J. Hofmann, Rudolph P., Jr. Holloway, Sheryl S. Klima-Silberg, Catherine I. Kluth, Daniel J. Lemaire, Charles A.	Reg. No. 35,138 Reg. No. 30,837 Reg. No. 37,346 Reg. No. 38,187 Reg. No. 37,850 Reg. No. 40,052 Reg. No. 32,146 Reg. No. 36,198	Litman, Mark A. Lundberg, Steven W. Madrid, Andres N. Schwegman, Micheal L. Simboli, Paul B. Slifer, Russell D. Viksnins, Ann S. Woessner, Warren D.	Reg. No. 26,390 Reg. No. 30,568 Reg. No. 40,710 Reg. No. 25,816 Reg. No. 38,616 Reg. No. 39,838 Reg. No. 37,748 Reg. No. 30,440
--	---	--	--	--	--

I hereby authorize them to act and rely on instructions from and communicate directly with the person/assignee/attorney/ firm/organization/who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct Schwegman, Lundberg, Woessner & Kluth, P.A. to the contrary.

Please direct all correspondence in this case to Schwegman, Lundberg, Woessner & Kluth, P.A. at the address indicated below: P.O. Box 2938, Minneapolis, MN 55402

Telephone No. (612)373-6900





Filing Date: December 16, 1997

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of sole inventor Citizenship: Post Office Address: Signature:	Bianca M. Conti-Fine United States of America 2424 Lake Place Minneapolis, MN 55405 Bianca M. Conti-Fine	Residence: Minne	3/23/98
Full Name of inventor: Citizenship: Post Office Address:		Residence:	
Signature:		Date:	
Full Name of inventor: Citizenship: Post Office Address:		Residence:	
Signature:		Date:	
Full Name of inventor: Citizenship: Post Office Address:		Residence:	
Signature:		Date:	

Our Ref. 600.423US1 Serial No. 08/991,143 Filing Date: December 16, 1997

§ 1.56 Duty to disclose information material to patentability.

- (a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:
 - (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
 - (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.
- (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and
 - (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
 - (2) It refutes, or is inconsistent with, a position the applicant takes in:
 - (i) Opposing an argument of unpatentability relied on by the Office, or
 - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

- (c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:
 - (1) Each inventor named in the application:
 - (2) Each attorney or agent who prepares or prosecutes the application; and
 - (3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.
- (d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.